Merck & Co (NY:MRK)

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

February 23, 2026

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Via Stocktwits

Topics Intellectual Property

Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades ↗

February 22, 2026

The company might bend, but it won't break.

Merck & Co. Inc. (NYSE:MRK) Emerges as a Strong Dividend Contender Through Methodical Screening ↗

Topics Intellectual Property

February 19, 2026

Via Chartmill

Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement? ↗

February 22, 2026

Merck has an attractive yield and a long history of dividend growth.

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...

Topics Intellectual Property

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

Via Finterra

Topics Lawsuit

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

February 19, 2026

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

February 18, 2026

From Merck & Co., Inc. and Mayo Clinic

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

Via Finterra

Topics Economy Intellectual Property

Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗

February 17, 2026

The comments come as ImmunityBio pushes for broader global access to Anktiva across indications.

Via Stocktwits

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

All 8 stocks with big upside

Topics Intellectual Property

8 Cheap Stocks to Buy in 2026 ↗

February 16, 2026

These two stocks have historically zigged when the market has zagged.

2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗

February 14, 2026

And now may be the right time to look for something other than artificial intelligence (AI)-driven growth.

Topics Stocks

Prediction: These Could Be the Best-Performing Value Stocks Through 2030 ↗

February 14, 2026

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

Topics Artificial Intelligence Intellectual Property

February 13, 2026

Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s...

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

Topics Earnings

Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗

February 13, 2026

The Dow Jones Industrial Average endured a chilling session this Friday, February 13, 2026, dropping 267.77 points, or 0.54%, to close at 49,184.21. The slide marked the second consecutive day of...

Dow Jones 267-Point Slide: Blue-Chip Leaders and the AI Reality Check

February 13, 2026

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their...

Topics Artificial Intelligence Bonds Economy

3 Mega-Cap Stocks for Long-Term Investors

February 12, 2026

Via StockStory

Topics Supply Chain

The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle

February 12, 2026

The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven...

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying...

Topics Artificial Intelligence Economy Energy

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026,...

Topics Artificial Intelligence Bonds Economy

Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market

February 12, 2026

Via Finterra

Topics Artificial Intelligence Earnings Economy

The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation

February 12, 2026

The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of...

Via Finterra

Topics Initial Public Offering Intellectual Property

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

February 12, 2026

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

February 11, 2026

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

Topics Artificial Intelligence Earnings Economy

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

5 Revealing Analyst Questions From Merck’s Q4 Earnings Call

February 10, 2026

Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact of several new product launches and strategic acquisitions. Management...

Via StockStory

Topics Earnings Intellectual Property

Stock Market Today, Feb. 9: Oracle Climbs on AI Optimism Despite Software Sector Weakness ↗

February 09, 2026

On Feb. 9, 2026, Oracle's AI-fueled advance helped steady major U.S. indexes as software lagged and traders eyed key macro data.

You always get what you pay for, so don't be afraid to pay up for a little more quality.

Topics Artificial Intelligence Economy Stocks

3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 ↗

February 08, 2026